Background: Rhopalurus junceus scorpion venom has shown potential for anticancer treatment. However, there are no scientific evidence about venom pharmacokinetic (PK) and biodistribution (BD) in tumor-bearing mice.
Methods: 131I-labeled venom was administrated by intravenous (IV) and oral (PO) routes at the single dose of 12.